Regulatory FDA approves new high dose Spinraza regimen for SMA PharmaTimesUpdated dosing offers meaningful clinical benefitRegulatoryRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Updated dosing offers meaningful clinical benefit RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Viridian reports positive results from elegrobart phase 3 trialNext: Ambrosia adds a megaround for obesity drugs Related Stories Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients pharminent June 2, 2026 Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026 Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026
